Download PDF
Semin Thromb Hemost 2009; 35(6): 560-567
DOI: 10.1055/s-0029-1240016
© Thieme Medical Publishers

Management Strategies for Optimal Control of Anticoagulation in Patients with Atrial Fibrillation

Marcel Levi1 , 2 , Olaf R. de Peuter1 , Pieter W. Kamphuisen1
  • 1Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • 2Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Further Information

Publication History

Publication Date:
28 September 2009 (online)

    Permissions and Reprints

Abstract

Most patients with atrial fibrillation need anticoagulant treatment with vitamin K antagonists for prevention of thromboembolism, in particular ischemic stroke. Many studies show the efficacy of this treatment but also that it is difficult to keep patients who use vitamin K antagonists in the proper treatment range. Both a too low and a too high intensity of anticoagulation significantly increase the risk of adverse events. Hence repeated monitoring of the intensity of anticoagulation and dose adjustments are required. Management strategies that improve the time in the therapeutic target range are computer-assisted dosing algorithms and centralized care in anticoagulation clinics. In addition, self-testing of the international normalized ratio and self-dosing of vitamin K antagonists has been introduced over the past 20 years and has been shown to be an effective and safe treatment modality.

KEYWORDS

Anticoagulation - warfarin - coumarin - thrombosis - bleeding - atrial fibrillation

REFERENCES

  • 1 Singer D E, Albers G W, Dalen J E et al.. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 546S-592S
    CrossrefPubMedGoogle Scholar
  • 2 Finsterer J, Stollberger C. Strategies for primary and secondary stroke prevention in atrial fibrillation.  Neth J Med. 2008;  66 327-333
    PubMedGoogle Scholar
  • 3 Levi M, Hobbs F DR, Jacobson A K et al.. Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives.  Semin Thromb Hemost. 2009;  527-542
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126(3 suppl) 204S-233S
    CrossrefPubMedGoogle Scholar
  • 5 Hart R G, Benavente O, McBride R, Pearce L A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.  Ann Intern Med. 1999;  131 492-501
    PubMedGoogle Scholar
  • 6 Mannucci P M, Levi M. Prevention and treatment of major blood loss.  N Engl J Med. 2007;  356 2301-2311
    CrossrefPubMedGoogle Scholar
  • 7 Levi M, Hovingh G K, Cannegieter S C, Vermeulen M, Buller H R, Rosendaal F R. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based.  Blood. 2008;  111 4471-4476
    CrossrefPubMedGoogle Scholar
  • 8 Hirsh J. Oral anticoagulant drugs.  N Engl J Med. 1991;  324 1865-1875
    CrossrefPubMedGoogle Scholar
  • 9 O'Reilly R A, Aggeler P M. Determinants of the response to oral anticoagulant drugs in man.  Pharmacol Rev. 1970;  22 35-96
    PubMedGoogle Scholar
  • 10 Fairweather R B, Ansell J, van den Besselaar A M et al.. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy.  Arch Pathol Lab Med. 1998;  122 768-781
    PubMedGoogle Scholar
  • 11 Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 160S-198S
    CrossrefPubMedGoogle Scholar
  • 12 Geest-Daalderop J H, Hutten B A, Sturk A, Levi M M. Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.  J Thromb Thrombolysis. 2003;  15 197-203
    CrossrefPubMedGoogle Scholar
  • 13 van Geest-Daalderop J H, Hutten B A, Pequeriaux N C, Haas F J, Levi M, Sturk A. The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol.  Thromb Haemost. 2007;  98 738-746
    PubMedGoogle Scholar
  • 14 Kok G, Van Doben B, Mullen P D. Effectiveness of health education and health promotion: meta-analyses of effect studies and determinants of effectiveness.  Patient Educ Couns. 1997;  30 19-27
    CrossrefPubMedGoogle Scholar
  • 15 Beyth R J, Landefeld C S. Prevention of major bleeding in older patients treated with warfarin: results of a randomized trial.  J Gen Intern Med. 1997;  12 66
    PubMedGoogle Scholar
  • 16 Horstkotte D, Piper C, Wiemer M, Schulte H D, Schultheiss H P. Improvement of prognosis by home prothrombin estimation in patients with life-long anticoagulant therapy.  Eur Heart J. 1996;  17(suppl.) 230
    PubMedGoogle Scholar
  • 17 Sawicki P T. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation.  JAMA. 1999;  281 145-150
    CrossrefPubMedGoogle Scholar
  • 18 Matchar D B, Samsa G P, Cohen S J, Oddone E Z, Jurgelski A E. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial.  Am J Med. 2002;  113 42-51
    CrossrefPubMedGoogle Scholar
  • 19 Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study.  Lancet. 1994;  343 687-691
    PubMedGoogle Scholar
  • 20 van der Meer F J, Rosendaal F R, Vandenbroucke J P, Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.  Arch Intern Med. 1993;  153 1557-1562
    CrossrefPubMedGoogle Scholar
  • 21 The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.  N Engl J Med. 1990;  323 1505-1511
    CrossrefPubMedGoogle Scholar
  • 22 Petersen P, Boysen G, Godtfredsen J, Andersen E D, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.  Lancet. 1989;  1 175-179
    PubMedGoogle Scholar
  • 23 Cannegieter S C, Rosendaal F R, Wintzen A R, van der Meer F J, Vandenbroucke J P, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves.  N Engl J Med. 1995;  333 11-17
    CrossrefPubMedGoogle Scholar
  • 24 Ryan P J, Gilbert M, Rose P E. Computer control of anticoagulant dose for therapeutic management.  BMJ. 1989;  299 1207-1209
    CrossrefPubMedGoogle Scholar
  • 25 Poller L, Wright D, Rowlands M. Prospective comparative study of computer programs used for management of warfarin.  J Clin Pathol. 1993;  46 299-303
    CrossrefPubMedGoogle Scholar
  • 26 Poller L, Shiach C R, MacCallum P K et al.. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation.  Lancet. 1998;  352 1505-1509
    CrossrefPubMedGoogle Scholar
  • 27 Ageno W, Johnson J, Nowacki B, Turpie A G. A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy.  Thromb Haemost. 2000;  83 849-852
    PubMedGoogle Scholar
  • 28 van Geest-Daalderop J H, Hutten B A, Pequeriaux N C, Levi M, Sturk A. Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: prospective validation of a prescription model.  J Thromb Thrombolysis. 2009;  27(2) 207-214
    CrossrefPubMedGoogle Scholar
  • 29 Cortelazzo S, Finazzi G, Viero P et al.. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic.  , [see comments] Thromb Haemost. 1993;  69 316-320
    PubMedGoogle Scholar
  • 30 Errichetti A M, Holden A, Ansell J. Management of oral anticoagulant therapy. Experience with an anticoagulation clinic.  Arch Intern Med. 1984;  144 1966-1968
    CrossrefPubMedGoogle Scholar
  • 31 Ansell J E, Patel N, Ostrovsky D, Nozzolillo E, Peterson A M, Fish L. Long-term patient self-management of oral anticoagulation.  Arch Intern Med. 1995;  155 2185-2189
    CrossrefPubMedGoogle Scholar
  • 32 Palareti G, Leali N, Coccheri S et al.. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.  Lancet. 1996;  348 423-428
    CrossrefPubMedGoogle Scholar
  • 33 Fitzmaurice D A, Murray E T, Gee K M, Allan T F, Hobbs F D. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management.  J Clin Pathol. 2002;  55 845-849
    CrossrefPubMedGoogle Scholar
  • 34 Watzke H H, Forberg E, Svolba G, Jimenez-Boj E, Krinninger B. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation.  Thromb Haemost. 2000;  83 661-665
    PubMedGoogle Scholar
  • 35 van Es R F, Jonker J J, Verheugt F W, Deckers J W, Grobbee D E. Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.  Lancet. 2002;  360 109-113
    CrossrefPubMedGoogle Scholar
  • 36 Levi M. Haemostasis and thrombosis: new developments in treatment strategies.  Neth J Med. 2003;  61 8-12
    PubMedGoogle Scholar
  • 37 Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).  J Thromb Thrombolysis. 2007;  23 83-91
    CrossrefPubMedGoogle Scholar
  • 38 Nichol M B, Knight T K, Dow T et al.. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care.  Ann Pharmacother. 2008;  42 62-70
    PubMedGoogle Scholar
  • 39 Leaning K E, Ansell J E. Advances in the monitoring of oral anticoagulation: point-of-care testing, patient self-monitoring, and patient self-management.  J Thromb Thrombolysis. 1996;  3 377-383
    PubMedGoogle Scholar
  • 40 Tripodi A, Chantarangkul V, Clerici M, Negri B, Mannucci P M. Determination of the international sensitivity index of a new near-patient testing device to monitor oral anticoagulant therapy.  Thromb Haemost. 1997;  78 855-858
    PubMedGoogle Scholar
  • 41 Kitchen S, Preston F E. Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins.  J Clin Pathol. 1997;  50 951-956
    CrossrefPubMedGoogle Scholar
  • 42 Ansell J E. Empowering patients to monitor and manage oral anticoagulation therapy.  JAMA. 1999;  281 182-183
    CrossrefPubMedGoogle Scholar
  • 43 Levi M. Self-management of anticoagulation.  Expert Rev Cardiovasc Ther. 2008;  6 979-985
    CrossrefPubMedGoogle Scholar
  • 44 Fitzmaurice D A, Gardiner C, Kitchen S, Mackie I, Murray E T, Machin S J. An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation.  Br J Haematol. 2005;  131 156-165
    CrossrefPubMedGoogle Scholar
  • 45 Oberhardt B J, Dermott S C, Taylor M, Alkadi Z Y, Abruzzini A F, Gresalfi N J. Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis.  Clin Chem. 1991;  37 520-526
    CrossrefPubMedGoogle Scholar
  • 46 Kapiotis S, Quehenberger P, Speiser W. Evaluation of the new method CoaguChek for the determination of prothrombin time from capillary blood: comparison with Thrombotest on KC-1.  Thromb Res. 1995;  77 563-567
    CrossrefPubMedGoogle Scholar
  • 47 Machin S J, Mackie I J, Chitolie A, Lawrie A S. Near patient testing (NPT) in haemostasis—a synoptic review.  Clin Lab Haematol. 1996;  18 69-74
    CrossrefPubMedGoogle Scholar
  • 48 van den Besselaar A M, Breddin K, Lutze G et al.. Multicenter evaluation of a new capillary blood prothrombin time monitoring system.  Blood Coagul Fibrinolysis. 1995;  6 726-732
    CrossrefPubMedGoogle Scholar
  • 49 Cromheecke M E, Levi M, Colly L P et al.. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison.  Lancet. 2000;  356 97-102
    CrossrefPubMedGoogle Scholar
  • 50 Matchar D B, Jacobson A K, Edson R G et al.. The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481—the Home INR Study (THINRS).  J Thromb Thrombolysis. 2005;  19 163-172
    CrossrefPubMedGoogle Scholar
  • 51 Gadisseur A P, Breukink-Engbers W G, van der Meer F J, van den Besselaar A M, Sturk A, Rosendaal F R. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial.  Arch Intern Med. 2003;  163 2639-2646
    CrossrefPubMedGoogle Scholar
  • 52 Levi M, van der Meer F J, Cromheecke M E, de Mol B. Self-monitoring and self dosing of oral anticoagulant therapy with vitamin K antagonists.  Ned Tijdschr Geneeskd. 2001;  145 2313-2317
    PubMedGoogle Scholar
  • 53 Gadisseur A P, Kaptein A A, Breukink-Engbers W G, van der Meer F J, Rosendaal F R. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life.  J Thromb Haemost. 2004;  2 584-591
    CrossrefPubMedGoogle Scholar
  • 54 Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U. Self-management of oral anticoagulation in the elderly: rationale, design, baselines and oral anticoagulation control after one year of follow-up. A randomized controlled trial.  Thromb Haemost. 2007;  97 408-416
    PubMedGoogle Scholar
  • 55 Siebenhofer A, Berghold A, Sawicki P T. Systematic review of studies of self-management of oral anticoagulation.  Thromb Haemost. 2004;  91 225-232
    PubMedGoogle Scholar
  • 56 Heneghan C, Alonso-Coello P, Garcia-Alamino J M, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis.  Lancet. 2006;  367 404-411
    CrossrefPubMedGoogle Scholar
  • 57 Sullivan P W, Arant T W, Ellis S L, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.  Pharmacoeconomics. 2006;  24 1021-1033
    CrossrefPubMedGoogle Scholar
  • 58 Anderson D R, Harrison L, Hirsh J. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy.  Arch Intern Med. 1993;  153 1441-1447
    CrossrefPubMedGoogle Scholar
  • 59 Taborski U, Wittstamm F J, Bernardo A. Cost-effectiveness of self-managed anticoagulant therapy in Germany.  Semin Thromb Hemost. 1999;  25 103-108
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Jowett S, Bryan S, Murray E et al.. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis.  Br J Haematol. 2006;  134 632-639
    CrossrefPubMedGoogle Scholar
  • 61 Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease.  J Thromb Thrombolysis. 1998;  5 S19-S24
    CrossrefPubMedGoogle Scholar
  • 62 Sidhu P, O'Kane H O. Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients.  Ann Thorac Surg. 2001;  72 1523-1527
    CrossrefPubMedGoogle Scholar
  • 63 Hasenkam J M, Kimose H H, Knudsen L et al.. Self management of oral anticoagulant therapy after heart valve replacement.  Eur J Cardiothorac Surg. 1997;  11 935-942
    CrossrefPubMedGoogle Scholar
  • 64 Koertke H, Mainami K, Breymann T. INR self-management following mechanical heart valve replacement. Are education level and therapeutic compliance connected?.  J Thromb Thrombolysis. 2000;  9(suppl) S41-S46
    CrossrefPubMedGoogle Scholar
  • 65 Sunderji R, Gin K, Shalansky K et al.. A randomized trial of patient self-managed versus physician-managed oral anticoagulation.  Can J Cardiol. 2004;  20 1117-1123
    PubMedGoogle Scholar
  • 66 Voller H, Glatz J, Taborski U, Bernardo A, Dovifat C, Heidinger K. Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study).  Z Kardiol. 2005;  94 182-186
    PubMedGoogle Scholar
  • 67 Eitz T, Schenk S, Fritzsche D et al.. International normalized ratio self-management lowers the risk of thromboembolic events after prosthetic heart valve replacement.  Ann Thorac Surg. 2008;  85 949-954
    CrossrefPubMedGoogle Scholar
  • 68 White R H, McCurdy S A, von Marensdorff H, Woodruff Jr D E, Leftgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study.  Ann Intern Med. 1989;  111 730-737
    PubMedGoogle Scholar
  • 69 Cosmi B, Palareti G, Carpanedo M et al.. Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK).  Haematologica. 2000;  85 826-831
    PubMedGoogle Scholar
  • 70 Menendez-Jandula B, Souto J C, Oliver A et al.. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial.  Ann Intern Med. 2005;  142 1-10
    PubMedGoogle Scholar

Marcel LeviM.D. 

Department Internal Medicine, Academic Medical Centre F-4, Meibergdreef 9

1105 AZ Amsterdam, The Netherlands

Email: m.m.levi@amc.uva.nl